Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting

Virology

Volumn 230, Issue 2, 1997, Pages 265-274

  Richmond, J F L ^a   Mustafa, F ^a   Lu, S ^a   Santoro, J C ^a   Weng, J ^a   O'Connell, M ^a   Fenyo E M ^b   Hurwitz, J L ^c   Montefiori, D C ^d   Robinson, H L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; VACCINATION; VIRUS NEUTRALIZATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS; VACCINIA; VACCINIA VIRUS;

EID: 0030917744     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8478     Document Type: Article

References (53)

1. Alkhatib G., Combadiere C., Broder C. C., Feng Y., Kennedy P. E., Murphy P. M., Berger E. A. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
2. Berman P. W., Murthy K. K., Wrin T., Vennari J. C., Cobb E. K., Eastman D. J., Champe M., Nakamura G. R., Davison D., Powell M. F., Bussiere J., Francis D. P., Matthews T., Gregory T. J., Obijeski J. F. Protection of MN-rpg120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;52-59.
3. Boyer J. D., Wang B., Ugen K. E., Agadjanyan M., Javadian A., Frost P., Dang K., Carrano R. A., Ciccarelli R., Coney L., Williams W. V., Weiner D. B. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J. Med. Primatol. 25:1996;242-250.
4. Broder C. C., Earl P. L., Long D., Abedon S. T., Moss B., Doms R. W. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 91:1994;11699-11703.
5. Chapman B. S., Thayer R. M., Vincent K. A., Haigwood N. L. Effect of intron A from human cytomegalovirus (Towne) immediate early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19:1991;3979-3986.
6. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
7. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 318:1996;661-666.
8. Doranz B. J., Rucker J., Yi Y., Smyth R. J., Samson M., Peiper S. C., Parmentier M., Coffman R. G., Doms R. W. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 85:1996;1149-1158.
9. Dragic T., Litwin V., Allaway G. P., Martin S. R., Huang Y., Nagashima K. A., Cayanan C., Maddon P. J., Koup R. A., Moore J. P., Paxton W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
10. Earl P. L., Broder C. C., Long D., Lee S. A., Peterson J., Chakrabarti S., Doms R. W., Moss B. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody responses. J. Virol. 68:1994;3015-3026.
11. Earl P. L., Hügin A. W., Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64:1990;2448-2451.
12. Eisenbraun M. D., Fuller D. H., Haynes J. R. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12:1993;791-797.
13. Esparza J., Heyward W. L., Osmanov S. HIV vaccine development: From basic research to human trials. AIDS 1996. 10:1996;S123-S132.
14. Feng Y., Broder C. C., Kennedy P., Berger E. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:1996;872-877.
15. Fenyö E. M., Albert J., McKeating J. The role of the humoral immune response in HIV infection. AIDS 1996. 10:1996;S97-S106.
16. Fuerst T. R., Earl P. L., Moss B. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol. Cell. Biol. 7:1987;2538-2544.
17. Fuller D. H., Corb M. M., Barnett S., Steimer K., Haynes J. R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus monkeys. Vaccine. 1997.
18. Fuller D. H., Haynes J. R. A qualitative progression in HIV type 1 glycoprotein 12-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses. 10:1994;1433-1441.
19. Gartner S., Markovits P., Markovitz D. M., Kaplan M. H., Gallo R. C., Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 233:1986;215-219.
20. Hanson C. V. Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res. Hum. Retroviruses. 10:1994;645-648.
21. Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
22. Kahn J. O., Steimer K. S., Baenziger J., Duliege A-M., Feinberg M., Elbeik T., Chesney M., Murcar N., Chernoff D., Sinangail F. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:1995;1343-1347.
23. Kent K. A., Robinson J. Antigenic determinants on HIV-1 envelope glycoproteins: A Dickens of a time with oligomer twist. AIDS 1996. 10:1996;S107-S114.
24. Korber T. T. M., Allen E. E., Farmer A. D., Myers G. L. Heterogeneity of HIV-1 and HIV-2. AIDS 1995. 9:1995;S5-S18.
25. Koup R. A., Safrit J. T., Cao Y., Andrews C. A., Wu Y., McLeod G., Borkowsky W., Farthing C., Ho D. D. Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome. J. Virol. 68:1994;4650-4655.
26. Leong K. H., Ramsay A. J., Ramshaw I. A., Morin M. J., Robinson H. L., Boyle D. B. Generation of enhanced immune responses by consecutive immunization with DNA and recombinant fowl pox vectors. Vaccines. 95:1995;327-331.
27. Lu S., Santoro J. C., Fuller D. H., Haynes J. R., Robinson H. L. Use of DNAs expressing HIV-1 particles to raise antibody responses in mice. Virology. 209:1995;147-154.
28. Mascola J. R., Snyder S. W., Weislow O. S., Belay S. M., Belshe R. B., Schwartz D. H., Clements M. L., Dolin R., Graham B. S., Gorse G. J., Keefer M. C., McElrath M. J., Walker M. C., Wagner K. F., McNeil J. G., McCutchan F. E., Burke D. S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;340-348.
29. McElrath J. M., Corey L., Greenberg P. D., Matthews T. J., Montefiori D. C., Rowen L., Hood L., Mullins J. I. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA. 93:1996;3972-3977.
30. Montefiori D. C., Robinson W. E. Jr., Schuffman S. S., Mitchell W. M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26:1988;231-237.
31. Montefiori D. C., Pantaleo G., Fink L. M., Zhou J. T., Zhou Z. Y., Bilska M., Mirailes G. D., Fauci A. S. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173:1996;60-67.
32. Moore J. P., Cao Y., Qing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. 3rd, Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:1995;101-109.
33. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:1996;427-444.
34. Moore J. P., Ho D. D. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 1995. 9:1995;S117-S136.
35. Mustafa F., Richmond J. F. L., Fernandez-Larsson R., Lu S., Fredricksson R., Fenyö E. M., O'Connell M., Johnson E., Weng J., Santoro J. C., Robinson H. L. HIV-1 Env glycoproteins from two series of primary isolates: Replication phenotype and immunogenicity. Virology. 1997.
36. O'Brien W. A., Koyanagi Y., Namazie A., Zhao J. Q., Diagne A., Idler K., Zack J. A., Chen I. S. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature. 348:1990;69-73.
37. Okuda K., Bukawa H., Hamajima K., Kawamoto S., Sekigawa K., Yamada Y., Tanaka S., Ishii N., Aoki I., Nakamura M., Yamamoto H., Cullen B. R., Fukushima J. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1envrev. AIDS Res. Hum. Retroviruses. 11:1995;933-943.
38. S. D. Rencher, T. D. Lockey, R. Srinivas, R. J. Owens, J. L. Hurwitz, Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants, Vaccine.
39. Robinson J. E., Holton D., Lui J., McMurdo H., Murciano A., Gohd R. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J. Immunol. Methods. 132:1990;63-71.
40. Robinson H. L. DNA vaccines for immunodeficiency viruses. AIDS. 1997.
41. Robinson H. L., Feltquate D. M., Morin M. J. DNA vaccines: A new approach to vaccination. Vaccines 95: Molecular Approaches to the Control of Infectious Diseases. 1995;Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 69-75.
42. Ryan K. W., Owens R. J., Hurwitz J. L. Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. Lefkovits I. Immunology Methods Manual. 1997;Academic Press, London.
43. Shaw G. M., Hahn B. H., Arya S. K., Groopman J. E., Gallo R. C., Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science. 226:1984;1165-1171.
44. Stamatatos L., Cheng-Mayer C. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:1995;6191-6198.
45. Subbarao S., Schochetman G. Genetic variability of HIV-1. AIDS 1996. 10:1996;S13-S23.
46. VanCott T. C., Bethke F. R., Burke D. S., Redfield R. R., Birx D. L. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:1995;4100-4110.
47. VanCott T. C., Polonis V. R., Loomis L. D., Micheal N. L., Nara P. L., Birx D. L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses. 11:1995;1379-1391.
48. von Gegerfelt A., Albert J., Morfeldt-Månson L., Broliden K., Fenyö E. M. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology. 185:1991;162-168.
49. Wei X., Ghosh S. K., Taylor M. E., Johnson V. A., Emini E. A., Deutsch P., Lifson J. D., Boenhoeffer S., Nowak M. A., Hahn B. H., Saag M. S., Shaw G. M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
50. AIDS Res. Hum. Retroviruses. 10:1994;1327-1343.
51. Yasutomi W., Robinson H. L., Lu S., Mustafa F., Lekutis C., Arthos J., Mullins J. I., Voss G., Manson K., Wyand M., Letvin N. L. Simian immunodeficiency virus-specific cytotoxic T lymphocyte induction through DNA vaccination of rhesus monkeys. J. Virol. 70:1996;678-681.
52. Zhang L. I., Huang Y., He T., Cao Y., Ho D. D. HIV-1 Subtype and secondreceptor use. Nature. 383:1996;768.
53. Zhou J. Y., Montefiori D. C. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J. Virol. 71:1997;2512-2517.